Compare CSTE & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | CELU |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 56.7M |
| IPO Year | 2012 | N/A |
| Metric | CSTE | CELU |
|---|---|---|
| Price | $1.86 | $1.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 536.2K | 62.5K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $400,656,000.00 | $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $1.00 |
| 52 Week High | $5.04 | $4.35 |
| Indicator | CSTE | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 71.49 | 44.76 |
| Support Level | $0.86 | $1.62 |
| Resistance Level | $1.94 | $2.01 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 91.73 | 25.40 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.